Literature DB >> 1771970

One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine.

S Chutivongse1, H Wilde, D B Fishbein, G M Baer, T Hemachudha.   

Abstract

The 2-1-1 rabies postexposure treatment schedule is an abbreviated regimen in which a tissue culture rabies vaccine is administered intramuscularly at two sites on day 0, and at one site on days 7 and 21. Compared to the standard five-dose intramuscular regimen, the 2-1-1 schedule reduces the number of clinic visits from five to three and the amount of vaccine used by 20%. One hundred Thai patients, who were severely exposed to rabies, were treated with rabies immune globulin and the 2-1-1 regimen using purified Vero cell rabies vaccine. They were followed for 1 year. Rabies antibody titres were measured in 10% of this group. All patients survived and adverse reactions were mild. A satisfactory antibody response (a titre greater than 0.5 IU ml-1) occurred in all ten patients studied at day 14, but persisted for 90 days in 80% and for 360 days in only 50%. The authors therefore do not recommend use of the 2-1-1 schedule in severely exposed patients who also need to receive rabies immune globulin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1771970     DOI: 10.1016/0264-410x(91)90244-z

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group.

Authors:  J Lang; G H Simanjuntak; S Soerjosembodo; C Koesharyono
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

2.  A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.

Authors:  Jingchen Ma; Hongchang Wang; Jun Li; Likuan Chang; Yun Xie; Zhonglin Liu; Yuliang Zhao; Claudius Malerczyk; Malerczyk Claudius
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Zagreb regimen, an abbreviated intramuscular schedule for rabies vaccination.

Authors:  Jiangping Ren; Linong Yao; Jimin Sun; Zhenyu Gong
Journal:  Clin Vaccine Immunol       Date:  2014-11-12

4.  Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen).

Authors:  B J Mahendra; Dh Ashwath Narayana; Sharad Agarkhedkar; H S Ravish; B R Harish; Shalaka Agarkhedkar; S N Madhusudana; Ashwin Belludi; Khaleel Ahmed; Rekha Jonnalagedda; Hoshang Vakil; Chiranjiwi Bhusal; Ashwani Kumar Arora
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.

Authors:  Nianmin Shi; Yibin Zhang; Huizhen Zheng; Zhenggang Zhu; Dingming Wang; Sihai Li; Yuhua Li; Liqing Yang; Junnan Zhang; Yunhua Bai; Qiang Lu; Zheng Zhang; Fengji Luo; Chun Yu; Li Li
Journal:  Hum Vaccin Immunother       Date:  2017-01-25       Impact factor: 3.452

6.  Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers.

Authors:  Guihua Huang; Huazhang Liu; Qing Tang; Pengcheng Yu; Xinxin Shen; Yibin Zhang; Xiangyi Liu; Qing Cao; Chuanxi Fu; Beiyan Liu; Ming Wang
Journal:  Hum Vaccin Immunother       Date:  2013-09-05       Impact factor: 3.452

7.  Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study.

Authors:  Ravish H S; Akash Khobragade; Durga Satapathy; Monica Gupta; Surendra Kumar; Vinay Bhomia; Ramasubramanian V; Maharshi Desai; Ashok Dilipkumar Agrawal
Journal:  Hum Vaccin Immunother       Date:  2021-09-09       Impact factor: 4.526

8.  Safety and immunogenicity of rabies vaccine as 4 - dose Essen Intramuscular regimen for post exposure prophylaxis: A non - randomized, comparative controlled study.

Authors:  Ravish S Haradanahalli; Rupsa Banerjee; Mysore Sudarshan Kalappa; Ashwath Narayana; Rachana R Annadani; Gangaboraiah Bilagumba
Journal:  Hum Vaccin Immunother       Date:  2021-02-23       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.